Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
about
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeLarge-scale genetic study in East Asians identifies six new loci associated with colorectal cancer riskDifferential RelA- and RelB-dependent gene transcription in LTbetaR-stimulated mouse embryonic fibroblastsEnhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines.LTβR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells.Lymphotoxin β receptor activation promotes bladder cancer in a nuclear factor-κB-dependent manner.Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice.Clinical targeting of the TNF and TNFR superfamiliesLymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF-κB activation.Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD.Ectopic lymphoid tissues and local immunity.Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid TissuesLymphatics: at the interface of immunity, tolerance, and tumor metastasis.Orthotopic mouse models expressing fluorescent proteins for cancer drug discovery.Positive and negative influence of the matrix architecture on antitumor immune surveillance.Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity.Multi-specific antibodies for cancer immunotherapy.The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells.Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.A link between RelB expression and tumor progression in laryngeal cancer.Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.Drugs in Development for Hepatitis B.
P2860
Q28119095-F7EC7152-DBD8-435F-A69A-82EA0E0B82C5Q29417030-94307805-F4B0-4180-ABE2-422043BD7FB7Q33393459-FBFADC74-772C-47C6-9A8F-4B992BB39E2AQ34075052-FFC89FEA-32C9-4C03-994C-13FE837FD821Q34184469-2EF9A78D-9342-4528-AFBE-37F967121D3BQ34308847-91EB4CD2-A044-4DE8-BC40-6CBD1FACD8EFQ34549822-193195D9-2C4A-4FF1-9201-968DDA700266Q34673313-DA3EC451-FE9B-45CB-8AC9-4FDDB6159C6DQ36310211-495C7DEB-38BA-4199-A134-C76557EE2C8AQ36762882-BF8CA094-AECC-4A5A-9D21-81A06D18A28FQ36813972-78C3F0F3-9269-41D4-BBE2-A89BA411D9A8Q37066254-D75DB349-66F7-46F3-9483-DC6E262EA634Q37075235-5852CCEB-E894-4459-8C19-EB89FD158FC3Q37576573-02AFCF37-892C-4A11-AB96-F28BF74B3848Q37875904-AAAC8EF1-9365-4A24-AC25-B277F10EA7BEQ38028571-C675CB77-1A96-4BEC-A6D8-D390D33FA05EQ38104594-9C768120-CBC5-425F-B20B-E20799F088DBQ38172131-3B20C38C-6507-4E87-9F73-F2E18B339FDAQ38196723-5984705D-7B8D-4E3B-863E-8254A0A31A74Q38631619-DB252211-5FA8-4C40-A268-1C0D56D523EAQ38810926-F2C20D9D-5108-4D60-8AC8-15F1BFABB74CQ39021951-CA41BD4D-B8A1-4ABC-B000-E0B3C2852973Q39245218-D1EB0D3A-1068-4BBC-8876-3E1764930584Q39336527-C7CCEED9-440D-45D8-B222-5300B34EFC37Q39753915-C3F17029-7134-4E44-9F92-CD82B80E74FCQ39940476-4B1F476A-3ABB-4FEE-956F-0CD544B9F688Q40085069-3B82615C-A956-40F0-B8AA-2DBAFFEF4A78Q41369903-6A3A3A51-12DE-44F8-922B-91C00012EB92Q47646877-C083DAD3-E66C-4B1E-811F-E20A6FDF94F3Q48187016-28621528-EA8D-4458-BF6E-DAEBF06FD874Q52764230-A10FE0C2-C058-4BAA-A383-134FF7C95E39
P2860
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@ast
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@en
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@nl
type
label
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@ast
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@en
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@nl
prefLabel
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@ast
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@en
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@nl
P2093
P1433
P1476
Targeting the lymphotoxin-beta ...... as a potential cancer therapy.
@en
P2093
Alex Lukashin
Amie Carmillo
Apinya Ngam-ek
Cheryl Wilson
Cindy Bottiglio
Dajun Yang
Doreen LePage
Ellen Garber
Erika Silverio
Glenna Heaney
P304
P356
10.1158/0008-5472.CAN-06-0217
P407
P577
2006-10-01T00:00:00Z